BiotechTube

Lutathera

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuroendocrine Tumor G1 (NET G1)/Carcinoid

Conditions

Neuroendocrine Tumor G1 (NET G1)/Carcinoid, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors, Liver Metastases, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Neoplasm

Trial Timeline

Aug 2, 2024 → Oct 21, 2025

NCT ID
NCT05987176

About Lutathera

Lutathera is a phase 2 stage product being developed by Novartis for Neuroendocrine Tumor G1 (NET G1)/Carcinoid. The current trial status is terminated. This product is registered under clinical trial identifier NCT05987176. Target conditions include Neuroendocrine Tumor G1 (NET G1)/Carcinoid, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors.

What happened to similar drugs?

6 of 16 similar drugs in Neuroendocrine Tumor G1 (NET G1)/Carcinoid were approved

Approved (6) Terminated (2) Active (9)
✅Everolimus (RAD001)NovartisApproved
✅Pasireotide + DiazoxideNovartisApproved
✅everolimusNovartisApproved
✅sunitinibPfizerApproved
✅lanreotide acetateIpsenApproved
✅lanreotide (Autogel formulation)IpsenApproved
🔄Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.Jiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05987176Phase 2Terminated

Competing Products

20 competing products in Neuroendocrine Tumor G1 (NET G1)/Carcinoid

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT-α-NET + [212Pb]VMT-α-NETPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT-α-NETPerspective TherapeuticsPhase 1
27
[212Pb] VMT-α-NETPerspective TherapeuticsPhase 1
27
LenvatinibEisaiPhase 2
35
AbemaciclibEli LillyPhase 2
39
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.Jiangsu Hengrui MedicinePhase 3
47
FamitinibJiangsu Hengrui MedicinePhase 2
27
68Ga-DOTATOCJiangsu Hengrui MedicinePhase 3
47
OlaparibAstraZenecaPhase 2
27
AvelumabMerckPhase 1/2
32
PembrolizumabMerckPhase 2
27
Lenvatinib + Pembrolizumab + Hyperpolarized 13C-PyruvateMerckPhase 2
42
PembrolizumabMerckPhase 2
35
Pembrolizumab InjectionMerckPhase 2
27
Carboplatin + Cisplatin + Docetaxel + Etoposide + PembrolizumabMerckPhase 1
33
AvelumabMerckPhase 2
35
Pembrolizumab + LenvatinibMerckPhase 2
35
AvelumabMerckPhase 2
35
Pembrolizumab + Irinotecan + PaclitaxelMerckPhase 2
35
MK-0646MerckPhase 2
35